JP2020535436A5 - - Google Patents

Download PDF

Info

Publication number
JP2020535436A5
JP2020535436A5 JP2020518048A JP2020518048A JP2020535436A5 JP 2020535436 A5 JP2020535436 A5 JP 2020535436A5 JP 2020518048 A JP2020518048 A JP 2020518048A JP 2020518048 A JP2020518048 A JP 2020518048A JP 2020535436 A5 JP2020535436 A5 JP 2020535436A5
Authority
JP
Japan
Prior art keywords
fgf
treatment
subject
2sdng
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020518048A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020535436A (ja
JP7791649B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2018/076395 external-priority patent/WO2019063758A1/en
Publication of JP2020535436A publication Critical patent/JP2020535436A/ja
Publication of JP2020535436A5 publication Critical patent/JP2020535436A5/ja
Priority to JP2024064931A priority Critical patent/JP2024105273A/ja
Application granted granted Critical
Publication of JP7791649B2 publication Critical patent/JP7791649B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020518048A 2017-09-29 2018-09-28 Fgf-18化合物に対する反応性を予測する代謝バイオマーカー Active JP7791649B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024064931A JP2024105273A (ja) 2017-09-29 2024-04-12 Fgf-18化合物に対する反応性を予測する代謝バイオマーカー

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP17194220.4 2017-09-29
EP17194220 2017-09-29
EP18169324 2018-04-25
EP18169324.3 2018-04-25
PCT/EP2018/076395 WO2019063758A1 (en) 2017-09-29 2018-09-28 METABOLIC BIOMARKERS FOR PREDICTING RESPONSE TO FGF-18 COMPOUND

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024064931A Division JP2024105273A (ja) 2017-09-29 2024-04-12 Fgf-18化合物に対する反応性を予測する代謝バイオマーカー

Publications (3)

Publication Number Publication Date
JP2020535436A JP2020535436A (ja) 2020-12-03
JP2020535436A5 true JP2020535436A5 (cg-RX-API-DMAC7.html) 2021-11-11
JP7791649B2 JP7791649B2 (ja) 2025-12-24

Family

ID=63722380

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020518048A Active JP7791649B2 (ja) 2017-09-29 2018-09-28 Fgf-18化合物に対する反応性を予測する代謝バイオマーカー
JP2024064931A Withdrawn JP2024105273A (ja) 2017-09-29 2024-04-12 Fgf-18化合物に対する反応性を予測する代謝バイオマーカー

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024064931A Withdrawn JP2024105273A (ja) 2017-09-29 2024-04-12 Fgf-18化合物に対する反応性を予測する代謝バイオマーカー

Country Status (16)

Country Link
US (2) US11513128B2 (cg-RX-API-DMAC7.html)
EP (1) EP3687558B1 (cg-RX-API-DMAC7.html)
JP (2) JP7791649B2 (cg-RX-API-DMAC7.html)
CN (1) CN111163791A (cg-RX-API-DMAC7.html)
AU (1) AU2018343982B2 (cg-RX-API-DMAC7.html)
CA (1) CA3076029A1 (cg-RX-API-DMAC7.html)
DK (1) DK3687558T3 (cg-RX-API-DMAC7.html)
ES (1) ES2918250T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20220760T1 (cg-RX-API-DMAC7.html)
HU (1) HUE058786T2 (cg-RX-API-DMAC7.html)
IL (1) IL273613B2 (cg-RX-API-DMAC7.html)
LT (1) LT3687558T (cg-RX-API-DMAC7.html)
PL (1) PL3687558T3 (cg-RX-API-DMAC7.html)
RS (1) RS63293B1 (cg-RX-API-DMAC7.html)
SI (1) SI3687558T1 (cg-RX-API-DMAC7.html)
WO (1) WO2019063758A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2971315C (en) 2015-01-29 2023-02-14 Ares Trading S.A. Immunoassays for high positively charged proteins
LT3687558T (lt) 2017-09-29 2022-06-27 Merck Patent Gmbh Metaboliniai biožymenys, skirti atsako į fgf-18 junginį numatymui
RS63292B1 (sr) 2017-09-29 2022-06-30 Merck Patent Gmbh Inflamatorni biomarkeri za predviđanje responsivnosti na jedinjenje fgf-18
IL281333B2 (en) * 2018-09-10 2025-11-01 Merck Patent Gmbh A method for reducing risk in a clinical trial

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA75316C2 (uk) 1996-10-16 2006-04-17 Займодженетікс, Інк. Гомологи з фактором росту фібробласта
EP1551426B1 (en) 2002-10-07 2014-06-25 ZymoGenetics, Inc. Methods of administering fgf18
WO2004043237A2 (en) * 2002-11-08 2004-05-27 Barnes-Jewish Hospital Uncoupled collagen synthesis and degradation assays
DK1828239T3 (da) 2004-12-10 2011-12-19 Zymogenetics Inc FGF18-produktion i prokaryote værter
US8224579B2 (en) * 2005-06-17 2012-07-17 The Brigham And Women's Hospital, Inc. Method of diagnosing osteoarthritis
US20070292982A1 (en) 2006-06-16 2007-12-20 Jeffery Gail Holloway Method for Manufacturing Transparent Windows in Molded Semiconductor Packages
US8207115B2 (en) * 2006-08-25 2012-06-26 Ares Trading S.A. Treatment of cartilage disorders with FGF-18
JP2009257842A (ja) * 2008-04-14 2009-11-05 Ttc:Kk 変形性関節症の検査方法及び診断用キット
US20100098775A1 (en) 2008-05-02 2010-04-22 Interleukin Genetics, Inc. Detecting genetic predisposition to osteoarthritis associated conditions
US20090299769A1 (en) 2008-05-29 2009-12-03 Nordic Bioscience Imaging A/S Prognostic osteoarthritis biomarkers
US20120115137A1 (en) 2010-08-31 2012-05-10 Kornman Kenneth S Methods of Predicting Osteoarthritis
TWI527590B (zh) 2011-06-17 2016-04-01 艾瑞斯貿易公司 Fgf-18之凍乾調配物
EP2880179B1 (en) 2012-08-06 2017-12-13 Merck Patent GmbH Genetic markers for predicting responsiveness to fgf-18 compound
PL2880181T3 (pl) 2012-08-06 2019-03-29 Merck Patent Gmbh Biomarkery prognostyczne w zaburzeniach chrząstki
US9829493B2 (en) * 2013-07-15 2017-11-28 Steven J. Svoboda Methods and apparatus for assessment of risk for joint injury
TW201536320A (zh) 2013-12-02 2015-10-01 Abbvie Inc 治療骨性關節炎之組合物及方法
KR102434024B1 (ko) 2013-12-24 2022-08-22 아레스 트레이딩 에스.아. 알지네이트/콜라겐 히드로겔 중의 fgf-18 제형물
NZ721332A (en) 2013-12-24 2022-07-01 Ares Trading Sa Fgf-18 formulation in xyloglucan gels
ES2698117T3 (es) 2014-02-20 2019-01-31 Merck Patent Gmbh Implante que comprende FGF-18
KR102437057B1 (ko) 2014-02-20 2022-08-26 메르크 파텐트 게엠베하 이식편 이식 및 조직 공학 절차에 있어서의 fgf-18
HRP20181570T1 (hr) 2014-02-20 2018-11-30 Merck Patent Gmbh Režim doziranja spoja fgf-18
CA2971315C (en) 2015-01-29 2023-02-14 Ares Trading S.A. Immunoassays for high positively charged proteins
WO2017079759A1 (en) 2015-11-06 2017-05-11 Samumed, Llc 2-(1h-indazol-3-yl)-3h-imidazo[4,5-c]pyridines and their anti-inflammatory uses thereof
US9983214B2 (en) 2016-04-15 2018-05-29 Esm Technologies, Llc Method for evaluating articular joint therapeutics
RS63292B1 (sr) 2017-09-29 2022-06-30 Merck Patent Gmbh Inflamatorni biomarkeri za predviđanje responsivnosti na jedinjenje fgf-18
LT3687558T (lt) * 2017-09-29 2022-06-27 Merck Patent Gmbh Metaboliniai biožymenys, skirti atsako į fgf-18 junginį numatymui
IL281333B2 (en) 2018-09-10 2025-11-01 Merck Patent Gmbh A method for reducing risk in a clinical trial

Similar Documents

Publication Publication Date Title
Martinez Treatment of acute portal vein thrombosis by non-traditional anticoagulation
JP2013507968A5 (cg-RX-API-DMAC7.html)
Broz et al. Neuropilin (NRPs) related pathological conditions and their modulators
JP2020535423A5 (cg-RX-API-DMAC7.html)
RU2015144699A (ru) Адреномедуллин для направленной терапии по снижению кровяного давления
JP2015508063A5 (cg-RX-API-DMAC7.html)
Niehues et al. Mutations of the gene FNIP1 associated with a syndromic autosomal recessive immunodeficiency with cardiomyopathy and pre‐excitation syndrome.
CN107075473A (zh) 其中未分化细胞被去除的分化诱导的细胞群、其用途及其制备方法
HRP20191145T1 (hr) Postupak predviđanja ishoda liječenja s afliberceptom kod pacijenta za kojeg se sumnja da ima rak
CN108697729A (zh) 新型GLUT抑制剂rapaglutin及其用途
JP2010500006A5 (cg-RX-API-DMAC7.html)
CA2819080A1 (en) Agtr1 as a marker for bevacizumab combination therapies
Ebrahimi et al. Dengue fever in Iran: A case report
CN105801700A (zh) 抗单核细胞白血病相关抗原MLAA-34全人源单克隆单链抗体ScFv
CN105745219A (zh) 结合β淀粉状蛋白的肽及其用于治疗和诊断阿尔茨海默痴呆症的用途
RU2014123166A (ru) Восприимчивость к ингибиторам ангиогенеза
JP2009538935A5 (cg-RX-API-DMAC7.html)
Pérez-Martínez et al. Magnetic resonance imaging and immunohistochemistry of primary vertebral hemangiosarcoma in a dog and implications for diagnosis and therapy
RU2014110271A (ru) Восприимчивость к ингибиторам ангиогенеза
ES2857513T3 (es) Oligonucleótidos y su uso
Smaili et al. CALR gene mutational profile in myeloproliferative neoplasms with non-mutated JAK2 in Moroccan patients: A case series and germline in-frame deletion
CN107987147A (zh) 一种mg53多聚体制备方法及其用途
JP2018500879A5 (cg-RX-API-DMAC7.html)
Murk et al. Persistent spiking fever in a child with acute myeloid leukemia and disseminated infection with enterovirus
A. Saad Zaghloul et al. Functional evaluation of imatinib mesylate in hepatocellular carcinoma cells